See the latest news and media coverage for CenExel. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical research site network
cenexel.comLast updated
In short: CenExel was set to be acquired after BayPine entered a definitive agreement.
Todd Bertoch, MD, served as a principal investigator on the clinical program for TYLENOL Professional with Naproxen, an over-the-counter fixed-dose combination of acetaminophen and naproxen sodium.
He joins with over 25 years of experience to lead technology and innovation efforts in clinical research.
Dr. Bertoch presented Phase 3 post-surgical pain data at PAINWeek 2026, highlighting CenExel's role in the Kenvue-sponsored program.
The Phase 2b trial evaluated LTG-001, an NaV1.8 inhibitor, and found significant pain reduction versus placebo; the high-dose group also required less opioid rescue.
/PRNewswire/ -- CenExel Clinical Research ("CenExel" or the "Company"), a leading, wholly-owned clinical research site network, today announced the appointment...
BOSTON--(BUSINESS WIRE)--BayPine LP (“BayPine”), a private investment firm that drives digital transformation in market-leading businesses, today announced that it has entered into a definitive ...
Salt Lake City, Utah, May 03, 2022 (GLOBE NEWSWIRE) -- CenExel announces the acquisition of iResearch ("CenExel iResearch"), a leading multi-specialty research site business with...
CenExel Clinical Research has acquired ForCare Clinical Research (CenExel FCR) to boost the support it provides for clinical research across a variety of therapeutic areas...
Track CenExel and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to CenExel and other trending companies.
